Barclays PLC Has $339,000 Holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

Barclays PLC lifted its position in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) by 201.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 78,151 shares of the company’s stock after purchasing an additional 52,265 shares during the period. Barclays PLC owned 0.14% of Black Diamond Therapeutics worth $339,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. Vestal Point Capital LP grew its position in shares of Black Diamond Therapeutics by 139.5% during the 3rd quarter. Vestal Point Capital LP now owns 5,028,500 shares of the company’s stock worth $21,874,000 after purchasing an additional 2,928,500 shares in the last quarter. Geode Capital Management LLC grew its position in Black Diamond Therapeutics by 12.2% during the third quarter. Geode Capital Management LLC now owns 944,877 shares of the company’s stock worth $4,111,000 after buying an additional 102,445 shares in the last quarter. Ally Bridge Group NY LLC acquired a new position in Black Diamond Therapeutics in the 2nd quarter valued at $3,891,000. State Street Corp lifted its position in shares of Black Diamond Therapeutics by 17.2% during the 3rd quarter. State Street Corp now owns 809,196 shares of the company’s stock valued at $3,520,000 after acquiring an additional 118,764 shares during the period. Finally, Point72 Asset Management L.P. bought a new position in shares of Black Diamond Therapeutics in the third quarter worth $3,032,000. 95.47% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on BDTX shares. Piper Sandler upped their price target on shares of Black Diamond Therapeutics from $12.00 to $15.00 and gave the stock an “overweight” rating in a report on Monday, September 23rd. HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of Black Diamond Therapeutics in a report on Wednesday, November 6th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $16.00 price objective on shares of Black Diamond Therapeutics in a research note on Tuesday, October 8th.

Black Diamond Therapeutics Stock Down 0.5 %

NASDAQ BDTX opened at $2.20 on Monday. Black Diamond Therapeutics, Inc. has a twelve month low of $1.91 and a twelve month high of $7.66. The business’s fifty day moving average is $2.40 and its 200 day moving average is $3.95. The company has a market cap of $124.48 million, a price-to-earnings ratio of -1.65 and a beta of 2.49.

Black Diamond Therapeutics (NASDAQ:BDTX) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.09. On average, research analysts anticipate that Black Diamond Therapeutics, Inc. will post -1.3 earnings per share for the current fiscal year.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.